Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ionis Pharmaceuticals Inc (IONS) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ionis Pharmaceuticals Inc. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 874015.
Total stock buying since 2015: $477,900.
Total stock sales since 2015: $220,707,715.
Total stock option exercises since 2015: $87,022,179.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 15,000 | $477,900 | 993,870 | $54,623,894 | 1,107,680 | $26,972,189 |
| 2024 | 0 | $0 | 216,854 | $10,417,483 | 306,713 | $1,690,800 |
| 2023 | 0 | $0 | 480,350 | $22,469,267 | 633,770 | $17,444,961 |
| 2022 | 0 | $0 | 9,319 | $373,594 | 272,987 | $291,150 |
| 2021 | 0 | $0 | 128,563 | $7,483,627 | 277,627 | $139,500 |
| 2020 | 0 | $0 | 435,149 | $22,468,509 | 430,271 | $8,790,881 |
| 2019 | 0 | $0 | 528,804 | $37,414,368 | 631,186 | $18,611,478 |
| 2018 | 0 | $0 | 237,729 | $11,778,492 | 331,168 | $2,959,654 |
| 2017 | 0 | $0 | 327,296 | $17,001,714 | 394,558 | $3,417,846 |
| 2016 | 0 | $0 | 240,936 | $9,522,537 | 302,772 | $2,241,037 |
| 2015 | 0 | $0 | 422,957 | $27,154,230 | 458,215 | $4,462,683 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-10-05 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 1,000 | 9.04 | 9,035 |
| 2017-10-04 | Crooke Stanley T (Chairman and CEO) | Sale | 11,000 | 54.23 | 596,475 |
| 2017-10-04 | Crooke Stanley T (Chairman and CEO) | Option Ex | 11,000 | 10.97 | 120,670 |
| 2017-10-02 | Crooke Stanley T (Chairman and CEO) | Sale | 16,500 | 52.00 | 858,000 |
| 2017-10-02 | Crooke Stanley T (Chairman and CEO) | Option Ex | 16,500 | 10.97 | 181,005 |
| 2017-09-06 | O'neil Patrick R. (SVP, Legal and General Counsel) | Sale | 800 | 55.00 | 44,000 |
| 2017-09-06 | O'neil Patrick R. (SVP, Legal and General Counsel) | Option Ex | 800 | 7.25 | 5,800 |
| 2017-09-05 | O'neil Patrick R. (SVP, Legal and General Counsel) | Sale | 200 | 55.00 | 11,000 |
| 2017-09-05 | O'neil Patrick R. (SVP, Legal and General Counsel) | Option Ex | 200 | 7.25 | 1,450 |
| 2017-07-24 | Bennett C Frank (SVP, Antisense Research) | Sale | 10,000 | 59.29 | 592,900 |
| 2017-07-24 | Bennett C Frank (SVP, Antisense Research) | Option Ex | 10,000 | 10.29 | 102,899 |
| 2017-07-20 | Crooke Stanley T (Chairman and CEO) | Sale | 11,000 | 55.35 | 608,850 |
| 2017-07-20 | Crooke Stanley T (Chairman and CEO) | Option Ex | 11,000 | 10.97 | 120,670 |
| 2017-07-17 | Crooke Stanley T (Chairman and CEO) | Sale | 16,500 | 52.45 | 865,425 |
| 2017-07-17 | Crooke Stanley T (Chairman and CEO) | Option Ex | 16,500 | 10.97 | 181,005 |
| 2017-07-03 | Monia Brett P (SVP, Antisense Drug Discovery) | Sale | 309 | 51.35 | 15,867 |
| 2017-07-03 | Crooke Stanley T (Chairman and CEO) | Sale | 16,500 | 52.16 | 860,640 |
| 2017-07-03 | Crooke Stanley T (Chairman and CEO) | Option Ex | 16,500 | 9.73 | 160,545 |
| 2017-07-02 | Klein Joseph Iii (Director) | Option Ex | 2,469 | .00 | 0 |
| 2017-07-01 | Castleman Breaux (Director) | Option Ex | 3,406 | .00 | 0 |
| 2017-07-01 | Loscalzo Joseph (Director) | Option Ex | 2,001 | .00 | 0 |
| 2017-07-01 | Muto Frederick T (Director) | Option Ex | 2,469 | .00 | 0 |
| 2017-07-01 | Berthelsen Spencer R (Director) | Option Ex | 2,469 | .00 | 0 |
| 2017-07-01 | Wender Joseph H (Director) | Option Ex | 2,469 | .00 | 0 |
| 2017-06-01 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 70 | 48.00 | 3,360 |
| 2017-06-01 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 70 | 10.82 | 757 |
| 2017-05-31 | Muto Frederick T (Director) | Sale | 12,500 | 45.22 | 565,250 |
| 2017-05-31 | Muto Frederick T (Director) | Option Ex | 12,500 | 9.77 | 122,125 |
| 2017-05-01 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 650 | 48.75 | 31,687 |
| 2017-05-01 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 500 | 10.82 | 5,410 |
| 2017-04-25 | Crooke Stanley T (Chairman and CEO) | Sale | 16,500 | 47.81 | 788,865 |
| 2017-04-25 | Crooke Stanley T (Chairman and CEO) | Option Ex | 16,500 | 7.25 | 119,625 |
| 2017-04-24 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 500 | 45.00 | 22,500 |
| 2017-04-24 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 500 | 10.82 | 5,410 |
| 2017-04-19 | Crooke Stanley T (Chairman and CEO) | Sale | 5,500 | 43.25 | 237,875 |
| 2017-04-19 | Crooke Stanley T (Chairman and CEO) | Option Ex | 5,500 | 7.25 | 39,875 |
| 2017-04-13 | Crooke Stanley T (Chairman and CEO) | Sale | 11,000 | 41.30 | 454,299 |
| 2017-04-13 | Crooke Stanley T (Chairman and CEO) | Option Ex | 11,000 | 8.26 | 90,893 |
| 2017-04-12 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 1,000 | 40.07 | 40,070 |
| 2017-04-12 | Crooke Stanley T (Chairman and CEO) | Sale | 11,000 | 40.07 | 440,770 |
| 2017-04-12 | Crooke Stanley T (Chairman and CEO) | Option Ex | 11,000 | 8.77 | 96,470 |
| 2017-03-03 | Bennett C Frank (SVP, Antisense Research) | Sale | 5,000 | 55.00 | 275,000 |
| 2017-03-03 | Bennett C Frank (SVP, Antisense Research) | Option Ex | 5,000 | 10.29 | 51,449 |
| 2017-03-02 | Crooke Stanley T (Chairman and CEO) | Sale | 12,100 | 51.05 | 617,705 |
| 2017-03-02 | Crooke Stanley T (Chairman and CEO) | Option Ex | 12,100 | 8.77 | 106,117 |
| 2017-03-01 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 1,500 | 49.29 | 73,935 |
| 2017-03-01 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 500 | 10.82 | 5,410 |
| 2017-03-01 | Parshall B Lynne (COO) | Sale | 4,625 | 49.26 | 227,827 |
| 2017-03-01 | Parshall B Lynne (COO) | Option Ex | 4,625 | 14.69 | 67,941 |
| 2017-02-24 | Berthelsen Spencer R (Director) | Option Ex | 12,500 | 9.77 | 122,125 |
| 2017-02-06 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 1,500 | 46.34 | 69,502 |
| 2017-02-06 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 500 | 9.04 | 4,517 |
| 2017-02-03 | Loscalzo Joseph (Director) | Option Ex | 937 | .00 | 0 |
| 2017-01-17 | Boyce Sarah (Chief Business Officer) | Sale | 1,361 | 46.29 | 63,000 |
| 2017-01-17 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 2,246 | 46.29 | 103,969 |
| 2017-01-17 | Monia Brett P (SVP, Antisense Drug Discovery) | Sale | 2,502 | 46.29 | 115,817 |
| 2017-01-17 | Geary Richard S (SVP, Development) | Sale | 2,441 | 46.29 | 112,996 |
| 2017-01-17 | Hougen Elizabeth L (SVP, Finance & CFO) | Sale | 2,273 | 46.29 | 105,219 |
| 2017-01-17 | Bennett C Frank (SVP, Antisense Research) | Sale | 2,421 | 46.29 | 112,068 |
| 2017-01-17 | Parshall B Lynne (COO) | Sale | 7,246 | 46.29 | 335,417 |
| 2017-01-17 | Crooke Stanley T (Chairman and CEO) | Sale | 15,957 | 46.29 | 738,649 |
| 2017-01-15 | Boyce Sarah (Chief Business Officer) | Option Ex | 3,483 | .00 | 0 |
| 2017-01-15 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 5,745 | .00 | 0 |
| 2017-01-15 | Monia Brett P (SVP, Antisense Drug Discovery) | Option Ex | 6,402 | .00 | 0 |
| 2017-01-15 | Geary Richard S (SVP, Development) | Option Ex | 6,246 | .00 | 0 |
| 2017-01-15 | Hougen Elizabeth L (SVP, Finance & CFO) | Option Ex | 5,814 | .00 | 0 |
| 2017-01-15 | Bennett C Frank (SVP, Antisense Research) | Option Ex | 6,195 | .00 | 0 |
| 2017-01-15 | Parshall B Lynne (COO) | Option Ex | 16,033 | .00 | 0 |
| 2017-01-15 | Crooke Stanley T (Chairman and CEO) | Option Ex | 29,834 | .00 | 0 |
| 2017-01-10 | Crooke Stanley T (Chairman and CEO) | Sale | 13,200 | 49.25 | 650,100 |
| 2017-01-10 | Crooke Stanley T (Chairman and CEO) | Option Ex | 13,200 | 8.77 | 115,764 |
| 2017-01-04 | Crooke Stanley T (Chairman and CEO) | Sale | 7,700 | 50.10 | 385,770 |
| 2017-01-04 | Crooke Stanley T (Chairman and CEO) | Option Ex | 7,700 | 8.77 | 67,529 |
| 2017-01-03 | Monia Brett P (SVP, Antisense Drug Discovery) | Sale | 309 | 48.60 | 15,017 |
| 2017-01-03 | Crooke Stanley T (Chairman and CEO) | Sale | 11,000 | 48.05 | 528,550 |
| 2017-01-03 | Crooke Stanley T (Chairman and CEO) | Option Ex | 11,000 | 8.77 | 96,470 |
| 2016-12-20 | Monia Brett P (SVP, Antisense Drug Discovery) | Sale | 130 | 52.48 | 6,822 |
| 2016-12-15 | Parshall B Lynne (COO) | Sale | 4,000 | 50.00 | 200,000 |
| 2016-12-15 | Parshall B Lynne (COO) | Option Ex | 4,000 | 7.25 | 29,000 |
| 2016-12-05 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 350 | 45.00 | 15,750 |
| 2016-12-05 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 350 | 10.82 | 3,787 |
| 2016-12-05 | Hougen Elizabeth L (SVP, Finance & CFO) | Sale | 2,500 | 46.05 | 115,125 |
| 2016-12-05 | Hougen Elizabeth L (SVP, Finance & CFO) | Option Ex | 2,500 | 11.27 | 28,175 |
| 2016-12-01 | Parshall B Lynne (COO) | Sale | 12,500 | 42.33 | 529,125 |
| 2016-12-01 | Parshall B Lynne (COO) | Option Ex | 12,500 | 14.69 | 183,625 |
| 2016-11-14 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 1,000 | 45.00 | 45,000 |
| 2016-11-14 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 1,000 | 10.82 | 10,820 |
| 2016-11-14 | Hougen Elizabeth L (SVP, Finance & CFO) | Sale | 2,500 | 47.50 | 118,750 |
| 2016-11-14 | Hougen Elizabeth L (SVP, Finance & CFO) | Option Ex | 2,500 | 11.27 | 28,175 |
| 2016-11-11 | Hougen Elizabeth L (SVP, Finance & CFO) | Sale | 2,500 | 41.00 | 102,500 |
| 2016-11-11 | Hougen Elizabeth L (SVP, Finance & CFO) | Option Ex | 2,500 | 11.27 | 28,175 |
| 2016-11-10 | Crooke Stanley T (Chairman and CEO) | Sale | 11,000 | 41.23 | 453,475 |
| 2016-11-10 | Crooke Stanley T (Chairman and CEO) | Option Ex | 11,000 | 8.77 | 96,470 |
| 2016-11-09 | Hougen Elizabeth L (SVP, Finance & CFO) | Sale | 2,500 | 38.49 | 96,225 |
| 2016-11-09 | Hougen Elizabeth L (SVP, Finance & CFO) | Option Ex | 2,500 | 11.27 | 28,175 |
| 2016-11-09 | Bennett C Frank (SVP, Antisense Research) | Sale | 22,805 | 36.31 | 828,049 |
| 2016-11-09 | Bennett C Frank (SVP, Antisense Research) | Option Ex | 22,805 | 11.27 | 257,012 |
| 2016-11-09 | Crooke Stanley T (Chairman and CEO) | Sale | 22,000 | 36.50 | 803,000 |
| 2016-11-09 | Crooke Stanley T (Chairman and CEO) | Option Ex | 22,000 | 9.68 | 213,004 |
| 2016-11-07 | Bennett C Frank (SVP, Antisense Research) | Sale | 5,000 | 34.00 | 170,000 |
| 2016-11-07 | Bennett C Frank (SVP, Antisense Research) | Option Ex | 5,000 | 11.27 | 56,350 |
| 2016-10-05 | Crooke Stanley T (Chairman and CEO) | Sale | 11,000 | 36.61 | 402,710 |
| 2016-10-05 | Crooke Stanley T (Chairman and CEO) | Option Ex | 11,000 | 10.29 | 113,189 |
| 2016-09-27 | Crooke Stanley T (Chairman and CEO) | Sale | 22,000 | 36.03 | 792,769 |
| 2016-09-27 | Crooke Stanley T (Chairman and CEO) | Option Ex | 22,000 | 10.29 | 226,379 |
| 2016-09-21 | Crooke Stanley T (Chairman and CEO) | Sale | 22,000 | 35.50 | 781,000 |
| 2016-09-21 | Crooke Stanley T (Chairman and CEO) | Option Ex | 22,000 | 10.29 | 226,379 |
| 2016-09-01 | Parshall B Lynne (COO) | Sale | 12,500 | 29.93 | 374,162 |
| 2016-09-01 | Parshall B Lynne (COO) | Option Ex | 12,500 | 10.97 | 137,125 |
| 2016-07-02 | Klein Joseph Iii (Director) | Option Ex | 312 | .00 | 0 |
| 2016-07-02 | Muto Frederick T (Director) | Option Ex | 312 | .00 | 0 |
| 2016-07-02 | Berthelsen Spencer R (Director) | Option Ex | 312 | .00 | 0 |
| 2016-07-02 | Wender Joseph H (Director) | Option Ex | 312 | .00 | 0 |
| 2016-07-01 | Castleman Breaux (Director) | Option Ex | 2,740 | .00 | 0 |
| 2016-07-01 | Loscalzo Joseph (Director) | Option Ex | 1,334 | .00 | 0 |
| 2016-07-01 | Klein Joseph Iii (Director) | Option Ex | 1,803 | .00 | 0 |
| 2016-07-01 | Muto Frederick T (Director) | Option Ex | 1,803 | .00 | 0 |
| 2016-07-01 | Berthelsen Spencer R (Director) | Option Ex | 1,803 | .00 | 0 |
| 2016-07-01 | Wender Joseph H (Director) | Option Ex | 1,803 | .00 | 0 |
| 2016-05-31 | Muto Frederick T (Director) | Sale | 12,500 | 22.31 | 278,900 |
| 2016-05-31 | Muto Frederick T (Director) | Option Ex | 12,500 | 5.93 | 74,125 |
| 2016-04-06 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 1,000 | 45.00 | 45,000 |
| 2016-04-06 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 1,000 | 10.82 | 10,820 |
| 2016-04-06 | Crooke Stanley T (Chairman and CEO) | Sale | 11,000 | 46.12 | 507,375 |
| 2016-04-06 | Crooke Stanley T (Chairman and CEO) | Option Ex | 11,000 | 10.29 | 113,189 |
| 2016-03-31 | Crooke Stanley T (Chairman and CEO) | Sale | 11,000 | 40.73 | 448,085 |
| 2016-03-31 | Crooke Stanley T (Chairman and CEO) | Option Ex | 11,000 | 10.02 | 110,242 |
| 2016-03-23 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 1,000 | 45.40 | 45,400 |
| 2016-03-23 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 1,000 | 10.82 | 10,820 |
| 2016-02-19 | Berthelsen Spencer R (Director) | Option Ex | 12,500 | 5.93 | 74,125 |
| 2016-02-03 | Loscalzo Joseph (Director) | Option Ex | 938 | .00 | 0 |
| 2016-01-19 | Boyce Sarah (Chief Business Officer) | Sale | 872 | 41.46 | 36,150 |
| 2016-01-19 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 1,871 | 41.46 | 77,571 |
| 2016-01-19 | Monia Brett P (SVP, Antisense Drug Discovery) | Sale | 2,208 | 41.46 | 91,545 |
| 2016-01-19 | Geary Richard S (SVP, Development) | Sale | 2,162 | 41.46 | 89,634 |
| 2016-01-19 | Hougen Elizabeth L (SVP, Finance & CFO) | Sale | 1,899 | 41.46 | 78,740 |
| 2016-01-19 | Bennett C Frank (SVP, Antisense Research) | Sale | 2,110 | 41.46 | 87,474 |
| 2016-01-19 | Parshall B Lynne (COO & Secretary) | Sale | 5,192 | 41.46 | 215,260 |
| 2016-01-19 | Crooke Stanley T (Chairman and CEO) | Sale | 13,401 | 41.46 | 555,605 |
| 2016-01-15 | Boyce Sarah (Chief Business Officer) | Option Ex | 2,188 | .00 | 0 |
| 2016-01-15 | O'neil Patrick R. (SVP, Legal & General Counsel) | Option Ex | 4,693 | .00 | 0 |
| 2016-01-15 | Monia Brett P (SVP, Antisense Drug Discovery) | Option Ex | 5,543 | .00 | 0 |
| 2016-01-15 | Geary Richard S (SVP, Development) | Option Ex | 5,427 | .00 | 0 |
| 2016-01-15 | Hougen Elizabeth L (SVP, Finance & CFO) | Option Ex | 4,762 | .00 | 0 |
| 2016-01-15 | Bennett C Frank (SVP, Antisense Research) | Option Ex | 5,295 | .00 | 0 |
| 2016-01-15 | Parshall B Lynne (COO & Secretary) | Option Ex | 13,267 | .00 | 0 |
| 2016-01-15 | Crooke Stanley T (Chairman and CEO) | Option Ex | 24,661 | .00 | 0 |
| 2016-01-05 | Crooke Stanley T (Chairman and CEO) | Sale | 5,500 | 62.10 | 341,550 |
| 2016-01-05 | Crooke Stanley T (Chairman and CEO) | Option Ex | 5,500 | 9.76 | 53,652 |
| 2016-01-04 | O'neil Patrick R. (SVP, Legal & General Counsel) | Sale | 1,000 | 61.10 | 61,100 |
Insider trading activities including stock purchases, stock sales, and option exercises of IONS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ionis Pharmaceuticals Inc (symbol IONS, CIK number 874015) see the Securities and Exchange Commission (SEC) website.